Triphase Accelerator Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Triphase Accelerator Corporation
BTIG analyst expects SeaSpine’s acquisition of 7D Systems will help SeaSpine morph into a procedurally integrated solutions provider.
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.
- Other Names / Subsidiaries
- Nereus Pharmaceuticals Inc.
- Triphase Research & Development Corp.